Renewed interest in classic psychedelics as treatments for psychiatric disorders warrants a deeper understanding of their neural mechanisms. Single, high doses of psychedelic drugs have shown promise in treating depressive disorders, perhaps by reversing deficits in reward processing in the brain. In addition, there are anecdotal reports that repeated ingestion of low doses of LSD, or...
Journal of Medical Case ReportsJuly 17, 2022Ana Carolina Ruver-Martins, Maíra Assunção Bicca, Fabiano Soares de Araujo et al.
Abstract Background Cannabinoid-based therapy has been shown to be promising and is emerging as crucial for the treatment of cognitive deficits, mental illnesses, and many diseases considered incurable. There is a need to find an appropriate therapy for Alzheimer’s disease, and cannabinoid-based therapy appears to be a feasible possibility. Case presentation This report addresses the beneficial...
A psilocibina é um composto psicodélico de ocorrência natural produzido por mais de 200 espécies de fungos. Os mais potentes são membros do gênero Psilocybe, como P. azurescens, P. semilanceata e P. c
Classic psychedelics, including psilocybin, lysergic acid diethylamide (LSD), dimethyltryptamine, and mescaline, and entactogens/empathogens, especially 3,4-methylenedioxymethamphetamine, have received renewed attention in psychiatric research and may be developed into medications for such indications as anxiety, depression, cluster headache, and posttraumatic stress disorder, among others....
BackgroundThe practice of "microdosing," or the use of repeated, very low doses of lysergic acid diethylamide (LSD) to improve mood or cognition, has received considerable public attention, but empirical studies are lacking. Controlled studies are needed to investigate both the therapeutic potential and the neurobiological underpinnings of this pharmacologic treatment.MethodsThe present study...
This chapter is an introduction to the volume "Psychedelic Neuroscience" of Elsevier's Progress in Brain Research addressing the neurobiological mechanisms of psychedelic drugs, the resulting changes in brain activity and integration of traditional viewpoints. As the field is relatively new, there are discrepancies in the literature related to classification, composition and effects of the...
Psychedelics represent a potential breakthrough for treatment-resistant depression; however, the prolonged in-clinic monitoring required for compounds such as psilocybin and lysergic acid diethylamide is a logistical hurdle to widespread use. Intranasal mebufotenin (5-methoxy-N,N-dimethyltryptamine), a 5-hydroxytryptamine 1A (5-HT1A) and 5-HT2A agonist associated with brief psychedelic...
Background. Averaging the mean change in a suicidality score can hide a subgroup whose suicidal thoughts worsen in a particular stretch of days after psilocybin. Trials often do not enrol people with psychosis, bipolar disorder, or current high suicide risk. Objective. To assemble, from public sources only, what can actually be counted about treatment-emergent suicidal ideation or behaviour in...
Introduction Generalized anxiety disorder (GAD) is a chronic, disabling condition for which currently available pharmacotherapies have delayed onset, incomplete remission rates, treatment-emergent adverse effects and substantial real-world discontinuation. DT120, formerly MM120, is an investigational orally disintegrating tablet formulation of lysergide tartrate being developed as a single-dose...
Abstract Classic psychedelics, including lysergic acid diethylamide (LSD), are currently under investigation for the treatment of major depressive disorder (MDD). Cognitive dysfunction is common in MDD, but effects of psychedelic treatment on cognitive brain function, measured by magnetic resonance imaging, are sparsely reported. The present study investigated effects of LSD treatment on...